Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia

Shanique Palmer, Curtis A. Hanson, Clive S. Zent, Luis F. Porrata, Betsy LaPlant, Susan M. Geyer, Svetomir Nenad Markovic, Timothy G. Call, Deborah A. Bowen, Diane F Jelinek, Neil Elliot Kay, Tait D. Shanafelt

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Patients with chronic lymphocytic leukaemia (CLL) have a variable clinical course. The identification of modifiable characteristics related to CLL-specific survival may provide opportunities for therapeutic intervention. The absolute number of T-cell and natural killer (NK)-cells was calculated for 166 consecutive patients with CLL evaluated by flow cytometry at Mayo Clinic ≤2 months of diagnosis. The size of the T-cell/NK-cell compartment relative to the size of the malignant monoclonal B-cell (MBC) compartment was evaluated by calculating NK:MBC and T:MBC ratios. Patients exhibited substantial variation in the absolute number of T- and NK-cells as well as T:MBC and NK:MBC ratios at diagnosis. Higher T:MBC and NK:MBC ratios were observed among patients with early stage and mutated IGHV genes (all P ≤ 0.0003). As continuous variables, both T:MBC ratio (P-value = 0.03) and NK:MBC ratio (P-value = 0.02) were associated with time to treatment (TTT). On multivariate Cox modelling including stage, CD38, absolute MBC count, NK:MBC ratio and T:MBC ratio, the independent predictors of TTT were stage, T:MBC ratio and NK:MBC ratio. These findings suggest that measurable characteristics of the host immune system relate to the rate of disease progression in patients with newly diagnosed CLL. These characteristics can be modified and continued evaluation of immunomodulatory drugs, vaccination strategies and cellular therapies to delay/prevent disease progression are warranted.

Original languageEnglish (US)
Pages (from-to)607-614
Number of pages8
JournalBritish Journal of Haematology
Volume141
Issue number5
DOIs
StatePublished - Jun 2008

Fingerprint

Natural Killer T-Cells
B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Natural Killer Cells
Disease Progression
T-Lymphocytes
Drug Evaluation
Therapeutics

Keywords

  • Chronic lymphocytic leukaemia
  • Immune system
  • Natural killer cells
  • Prognosis
  • T-cells

ASJC Scopus subject areas

  • Hematology

Cite this

Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. / Palmer, Shanique; Hanson, Curtis A.; Zent, Clive S.; Porrata, Luis F.; LaPlant, Betsy; Geyer, Susan M.; Markovic, Svetomir Nenad; Call, Timothy G.; Bowen, Deborah A.; Jelinek, Diane F; Kay, Neil Elliot; Shanafelt, Tait D.

In: British Journal of Haematology, Vol. 141, No. 5, 06.2008, p. 607-614.

Research output: Contribution to journalArticle

Palmer, Shanique ; Hanson, Curtis A. ; Zent, Clive S. ; Porrata, Luis F. ; LaPlant, Betsy ; Geyer, Susan M. ; Markovic, Svetomir Nenad ; Call, Timothy G. ; Bowen, Deborah A. ; Jelinek, Diane F ; Kay, Neil Elliot ; Shanafelt, Tait D. / Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. In: British Journal of Haematology. 2008 ; Vol. 141, No. 5. pp. 607-614.
@article{2c6cdb7cafd54df8956a308f14789cc2,
title = "Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia",
abstract = "Patients with chronic lymphocytic leukaemia (CLL) have a variable clinical course. The identification of modifiable characteristics related to CLL-specific survival may provide opportunities for therapeutic intervention. The absolute number of T-cell and natural killer (NK)-cells was calculated for 166 consecutive patients with CLL evaluated by flow cytometry at Mayo Clinic ≤2 months of diagnosis. The size of the T-cell/NK-cell compartment relative to the size of the malignant monoclonal B-cell (MBC) compartment was evaluated by calculating NK:MBC and T:MBC ratios. Patients exhibited substantial variation in the absolute number of T- and NK-cells as well as T:MBC and NK:MBC ratios at diagnosis. Higher T:MBC and NK:MBC ratios were observed among patients with early stage and mutated IGHV genes (all P ≤ 0.0003). As continuous variables, both T:MBC ratio (P-value = 0.03) and NK:MBC ratio (P-value = 0.02) were associated with time to treatment (TTT). On multivariate Cox modelling including stage, CD38, absolute MBC count, NK:MBC ratio and T:MBC ratio, the independent predictors of TTT were stage, T:MBC ratio and NK:MBC ratio. These findings suggest that measurable characteristics of the host immune system relate to the rate of disease progression in patients with newly diagnosed CLL. These characteristics can be modified and continued evaluation of immunomodulatory drugs, vaccination strategies and cellular therapies to delay/prevent disease progression are warranted.",
keywords = "Chronic lymphocytic leukaemia, Immune system, Natural killer cells, Prognosis, T-cells",
author = "Shanique Palmer and Hanson, {Curtis A.} and Zent, {Clive S.} and Porrata, {Luis F.} and Betsy LaPlant and Geyer, {Susan M.} and Markovic, {Svetomir Nenad} and Call, {Timothy G.} and Bowen, {Deborah A.} and Jelinek, {Diane F} and Kay, {Neil Elliot} and Shanafelt, {Tait D.}",
year = "2008",
month = "6",
doi = "10.1111/j.1365-2141.2008.07070.x",
language = "English (US)",
volume = "141",
pages = "607--614",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia

AU - Palmer, Shanique

AU - Hanson, Curtis A.

AU - Zent, Clive S.

AU - Porrata, Luis F.

AU - LaPlant, Betsy

AU - Geyer, Susan M.

AU - Markovic, Svetomir Nenad

AU - Call, Timothy G.

AU - Bowen, Deborah A.

AU - Jelinek, Diane F

AU - Kay, Neil Elliot

AU - Shanafelt, Tait D.

PY - 2008/6

Y1 - 2008/6

N2 - Patients with chronic lymphocytic leukaemia (CLL) have a variable clinical course. The identification of modifiable characteristics related to CLL-specific survival may provide opportunities for therapeutic intervention. The absolute number of T-cell and natural killer (NK)-cells was calculated for 166 consecutive patients with CLL evaluated by flow cytometry at Mayo Clinic ≤2 months of diagnosis. The size of the T-cell/NK-cell compartment relative to the size of the malignant monoclonal B-cell (MBC) compartment was evaluated by calculating NK:MBC and T:MBC ratios. Patients exhibited substantial variation in the absolute number of T- and NK-cells as well as T:MBC and NK:MBC ratios at diagnosis. Higher T:MBC and NK:MBC ratios were observed among patients with early stage and mutated IGHV genes (all P ≤ 0.0003). As continuous variables, both T:MBC ratio (P-value = 0.03) and NK:MBC ratio (P-value = 0.02) were associated with time to treatment (TTT). On multivariate Cox modelling including stage, CD38, absolute MBC count, NK:MBC ratio and T:MBC ratio, the independent predictors of TTT were stage, T:MBC ratio and NK:MBC ratio. These findings suggest that measurable characteristics of the host immune system relate to the rate of disease progression in patients with newly diagnosed CLL. These characteristics can be modified and continued evaluation of immunomodulatory drugs, vaccination strategies and cellular therapies to delay/prevent disease progression are warranted.

AB - Patients with chronic lymphocytic leukaemia (CLL) have a variable clinical course. The identification of modifiable characteristics related to CLL-specific survival may provide opportunities for therapeutic intervention. The absolute number of T-cell and natural killer (NK)-cells was calculated for 166 consecutive patients with CLL evaluated by flow cytometry at Mayo Clinic ≤2 months of diagnosis. The size of the T-cell/NK-cell compartment relative to the size of the malignant monoclonal B-cell (MBC) compartment was evaluated by calculating NK:MBC and T:MBC ratios. Patients exhibited substantial variation in the absolute number of T- and NK-cells as well as T:MBC and NK:MBC ratios at diagnosis. Higher T:MBC and NK:MBC ratios were observed among patients with early stage and mutated IGHV genes (all P ≤ 0.0003). As continuous variables, both T:MBC ratio (P-value = 0.03) and NK:MBC ratio (P-value = 0.02) were associated with time to treatment (TTT). On multivariate Cox modelling including stage, CD38, absolute MBC count, NK:MBC ratio and T:MBC ratio, the independent predictors of TTT were stage, T:MBC ratio and NK:MBC ratio. These findings suggest that measurable characteristics of the host immune system relate to the rate of disease progression in patients with newly diagnosed CLL. These characteristics can be modified and continued evaluation of immunomodulatory drugs, vaccination strategies and cellular therapies to delay/prevent disease progression are warranted.

KW - Chronic lymphocytic leukaemia

KW - Immune system

KW - Natural killer cells

KW - Prognosis

KW - T-cells

UR - http://www.scopus.com/inward/record.url?scp=43449101911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449101911&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2008.07070.x

DO - 10.1111/j.1365-2141.2008.07070.x

M3 - Article

C2 - 18384436

AN - SCOPUS:43449101911

VL - 141

SP - 607

EP - 614

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -